By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Yale Spinoff Licenses HER3 Cancer Drug from MedImmune
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > Yale Spinoff Licenses HER3 Cancer Drug from MedImmune
FinanceMedical EducationSpecialties

Yale Spinoff Licenses HER3 Cancer Drug from MedImmune

Deanna Pogorelc
Deanna Pogorelc
Share
2 Min Read
SHARE

yale cancer drug HER3

Originally published at MedCityNews.com.

yale cancer drug HER3

Originally published at MedCityNews.com.

More Read

Image
Mobile Health Around the Globe: Connecting Caregivers of Aging Parents
Revenue Cycle Integrity Must Precede Data Analytics
Reducing Medical Denials Equals Increased Revenue
How Should Medical Professionals React to Men’s Health Emergencies?
How Laser Skin Rejuvenation Can Help You Look Younger

A cancer drug startup spun out of the Yale School of Medicine has licensed the rights to develop and test a drug candidate from MedImmune designed to target a receptor that’s been connected to various cancers, including breast, lung, ovary and colon.

Kolltan Pharmaceuticals hopes to have its lead candidate, which targets the HER3 receptor tyrosine kinase, in Phase 1 clinical trials in the first quarter of 2014. Company execs declined to specify which applications they’ll go after but said they believe the candidate has “broad potential” for treating cancer patients.

Under the deal with MedImmune, which is the global biologics R&D arm of AstraZeneca, both companies will have the potential for cost-, risk- and profit-sharing after early clinical testing. Financial details of the licensing agreement were not made public.

Kolltan was established in 2007 in collaboration with the lab of Dr. Joseph Schlessinger at Yale School of Medicine to develop new biologic drugs that target receptor tyrosine kinases.

Tyrosine kinases emerged more than a decade ago as clinically useful drug targets for treating certain kinds of cancers, and although  drugs that interfere with them have generally been successful, Kolltan says some patients experience resistance in later dosing cycles. The company thinks its mechanism of action will be unaffected by such resistance.

The New Haven, Connecticut-based company has raised at least $50 million from investors including Purdue Pharma, HBM BioCapital, Celtic Therapeutics Management, Tichenor Ventures and Osage University Partners. Its president and CEO, Jerry McMahon, joined Kolltan from MedImmune last year, where he was senior vice president of R&D oncology.

TAGGED:cancercancer drugHER3MedImmuneYale
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Epidemiological Health Benefits
Personal and Epidemiological Health Benefits of Blood Pressure Management
Health
October 13, 2025
Traumatic Brain Injuries
Understanding Traumatic Brain Injuries: What Families Need to Know
Policy & Law
October 10, 2025
Remote Monitoring touchpoints
Remote Monitoring Touchpoints Patients Will Actually Follow
Technology
October 9, 2025
dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025

You Might also Like

drCarson
BusinessFinanceHealth ReformPolicy & Law

Dr. Carson on Health Care

April 2, 2013

Another Pan Mass Challenge Enters the History Books

August 12, 2011

Facility Fees For Office Visits: What is the Role of Health Plans?

March 13, 2013
physicians and medicare payments
FinanceHealth ReformHospital AdministrationPolicy & Law

Physician Payments: The Not-So-Secret Secret

August 9, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?